Actinium Pharmaceuticals Advances ATNM-400 B7-H3 Candidate Into Phase 1 Clinical Trial in South Africa

Submit press release

Existing customer?
Log in

New customer?
Sign up

Latest Headlines
$400 Million ADB Loan to Improve Ease of Doing Business in the...
ADB Upgrades Asia and Pacific's Growth...
The Self-Service Revolution Reaches Employee...
Brooklyn Physical Therapy Launches Specialized Slip and Fall Injury...
First Person: Small acts, lasting impact, boost dignity for women in Lao...
Hong Kong: UN rights chief voices concern over 'draconian' laws, in wake...

M2 Archive: Preview

You haven't logged in. If you have archive credits in your account, please log in now to use them. If not, you can buy credits in our shopping area.

Actinium Pharmaceuticals Advances ATNM-400 B7-H3 Candidate Into Phase 1 Clinical Trial in South Africa

Actinium Pharmaceuticals (NYSE American: ATNM) is expanding its solid-tumor development efforts with the advancement of an ATNM-400 construct targeting B7-H3 into a Phase 1 clinical trial in South Africa. This represents one of the company's earliest human studies within its solid-tumor...

If you want to view the full text of this story, you must first purchase archive credits. Return to Archives
New Search